



LETTER TO SHAREHOLDERS

Los Angeles, September 11, 2018

Dear Shareholder,

We are pleased with the progress BioSig has made in completing a number of material milestones in 2018 and even more excited about how this has laid the foundation for the continued success of our Company.

In August we received the 510(k) clearance for our first commercial technology, the PURE EP™ System. Our advanced signal acquisition and processing system addresses unmet clinical needs in the rapidly growing \$4.6 billion dollar electrophysiology market. We hope to be able to provide better clinical information due to the higher resolution and enhanced signal clarity of our technology.

Soon after this we added Mrs. Amy Scott, a former Director of Strategic Partnerships at Biosense Webster, to our team to spearhead the commercial launch of this product and assist with the nationwide engagement of physicians. With over 30 years of experience in medical devices, including over 20 years in electrophysiology, Mrs. Scott brings to us extensive experience in defining customer needs and promoting key account relations and activities. Her role with us is focused on building relationships with physicians and clinics nationwide, as well as assist with commercialization efforts of the PURE EP™ System.

We anticipate the next several months to get even more exciting, as we get closer to the listing of our shares on the Nasdaq stock exchange and announce the first medical centers to receive our PURE EP™ System.

We are seeing steady interest throughout the United States and internationally, which confirms our belief that BioSig is well on its way to blossoming into a world-class market leader in the field of Bioelectronic Medicine.

Some other highlights include:

- We raised approximately \$12.5 million in 2018, which enabled us to solidify our balance sheet for the upcoming commercial milestones and qualified us for a Nasdaq uplisting – an opportunity to interest institutional shareholders in our Company.
- The 510(k) clearance led to an overnight change in how our Company has been perceived in the marketplace. We started seeing significant interest from solid medtech professionals, financial corporations and global medical institutions.



- To date, we published 9 peer review publications and presented at the prestigious 40th International Conference of the IEEE Engineering in Medicine and Biology Society in July this year.
- We have been named as one of the top [50 Most Innovative Companies to Watch](#) by the Silicon Review.
- We performed 13 pre-clinical studies at Mayo Clinic in Rochester, MN, and Mount Sinai in New York, NY. Now into the second year of our 10-year strategic collaboration with Mayo Clinic, we continue to build upon mutual IP interests.
- We will be collecting first-in-man data in the Q4 2018. We believe that this is a substantial milestone for our stakeholders.

To summarize, our Company is executing on all cylinders. We have increased the quality of our management team, fully funded our balance sheet, received FDA clearance and expect the uplisting to Nasdaq this year. We expect to continue to execute at these high levels and appreciate your continued support.

Kind regards,

Kenneth L. Londoner

A handwritten signature in blue ink that reads "Kenneth L. Londoner". The signature is fluid and cursive, with a long horizontal line extending from the end of the last name.

Chairman and CEO
BioSig Technologies, Inc.

